Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0001213900-23-025597
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $23.00K | — | — |
| Net Income | -$10.65M | -$8.01M | -$6.38M | -$4.60M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
